KALV
NASDAQ · Biotechnology
Kalvista Pharmaceuticals Inc
$17.00
+0.57 (+3.47%)
Financial Highlights (FY 2025)
Revenue
272.43M
Net Income
-77,974,346
Gross Margin
32.0%
Profit Margin
-28.6%
Rev Growth
+3.3%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 32.0% | 32.0% | 32.0% |
| Operating Margin | -32.2% | -31.2% | -31.4% |
| Profit Margin | -28.6% | -31.0% | -32.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 272.43M | 275.70M | 294.93M |
| Gross Profit | 87.18M | 88.23M | 94.38M |
| Operating Income | -87,704,275 | -85,953,547 | -92,707,107 |
| Net Income | -77,974,346 | -85,417,882 | -94,496,772 |
| Gross Margin | 32.0% | 32.0% | 32.0% |
| Operating Margin | -32.2% | -31.2% | -31.4% |
| Profit Margin | -28.6% | -31.0% | -32.0% |
| Rev Growth | +3.3% | +15.2% | -10.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 33.61M | 40.44M | 36.10M |
| Total Equity | 463.75M | 471.36M | 451.03M |
| D/E Ratio | 0.07 | 0.09 | 0.08 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -125,574,606 | -125,457,307 | -124,623,061 |
| Free Cash Flow | -59,177,907 | -68,220,346 | -69,677,831 |